The abstract is read at the publisher; the summary is JClub's.
In 14 pregnant patients treated with glecaprevir-pibrentasvir, 10 completed therapy and all achieved virologic response by or at delivery, with no maternal or neonatal safety concerns.
- Why it matters: Guidance supports antenatal hepatitis C treatment via shared decision making, but real-world evidence for glecaprevir-pibrentasvir during pregnancy has been lacking.
- What they did: The authors report real-world prenatal use of glecaprevir-pibrentasvir in 14 pregnant patients, tracking treatment completion and virologic response by delivery.
- The result: Among the 10 who finished treatment, virologic response was achieved by or at delivery, and the report found no maternal or neonatal safety concerns, supporting feasibility.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.